IN2012DN03348A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03348A
IN2012DN03348A IN3348DEN2012A IN2012DN03348A IN 2012DN03348 A IN2012DN03348 A IN 2012DN03348A IN 3348DEN2012 A IN3348DEN2012 A IN 3348DEN2012A IN 2012DN03348 A IN2012DN03348 A IN 2012DN03348A
Authority
IN
India
Prior art keywords
monoclonal antibodies
methods
progastrin
compositions
present disclosure
Prior art date
Application number
Inventor
Pannequin Julie
Boudier Laure
Joubert Dominique
Hollande Frederic
Original Assignee
Biorealites
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN03348(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biorealites, Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Biorealites
Publication of IN2012DN03348A publication Critical patent/IN2012DN03348A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Abstract

The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
IN3348DEN2012 2009-10-16 2010-10-15 IN2012DN03348A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25262509P 2009-10-16 2009-10-16
PCT/EP2010/006329 WO2011045080A2 (en) 2009-10-16 2010-10-15 Monoclonal antibodies to progastrin and their uses

Publications (1)

Publication Number Publication Date
IN2012DN03348A true IN2012DN03348A (en) 2015-10-23

Family

ID=43086711

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3348DEN2012 IN2012DN03348A (en) 2009-10-16 2010-10-15

Country Status (41)

Country Link
US (7) US9611320B2 (en)
EP (2) EP3421493B1 (en)
JP (3) JP5985987B2 (en)
KR (2) KR101640520B1 (en)
CN (2) CN104628857A (en)
AP (1) AP2012006262A0 (en)
AR (1) AR078659A1 (en)
AU (1) AU2010306119A1 (en)
BR (1) BR112012008818B1 (en)
CA (1) CA2777691C (en)
CL (1) CL2012000914A1 (en)
CR (1) CR20120184A (en)
CU (1) CU24196B1 (en)
CY (1) CY1120913T1 (en)
DK (1) DK2488551T3 (en)
EA (2) EA201791876A1 (en)
EC (1) ECSP12011796A (en)
ES (1) ES2690943T3 (en)
GE (1) GEP201706604B (en)
GT (1) GT201200114A (en)
HK (1) HK1178183A1 (en)
HN (1) HN2012000708A (en)
HR (1) HRP20181645T1 (en)
IL (2) IL219019B (en)
IN (1) IN2012DN03348A (en)
LT (1) LT2488551T (en)
MA (1) MA33747B1 (en)
MX (1) MX351635B (en)
NI (1) NI201200054A (en)
NZ (2) NZ599971A (en)
PE (1) PE20121649A1 (en)
PL (2) PL3421493T3 (en)
PT (1) PT2488551T (en)
RS (1) RS57966B1 (en)
SG (1) SG10201704933PA (en)
SI (1) SI2488551T1 (en)
TN (1) TN2012000159A1 (en)
TW (1) TWI537002B (en)
UA (1) UA106771C2 (en)
WO (1) WO2011045080A2 (en)
ZA (1) ZA201202642B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
LT2488551T (en) * 2009-10-16 2018-10-25 Progastrine Et Cancers S.A R.L. Monoclonal antibodies to progastrin and their uses
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
JP5829672B2 (en) * 2010-03-24 2015-12-09 レ ラボラトワール セルヴィエ Prevention of colorectal and gastrointestinal cancer
KR101576174B1 (en) * 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 Methods and compositions for liver cancer therapy
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
EP2715364A1 (en) 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
JP6450381B2 (en) * 2013-07-05 2019-01-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション Soluble MIC neutralizing monoclonal antibody for treating cancer
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
WO2015161311A2 (en) * 2014-04-18 2015-10-22 The Research Foundation For The State University Of New York Humanized anti-tf-antigen antibodies
WO2016066671A1 (en) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors
WO2017048629A1 (en) * 2015-09-15 2017-03-23 The Scripps Research Institute Antibodies for generating anti-inflammatory macrophage and related uses
CN114705858A (en) * 2015-12-31 2022-07-05 Syncerus有限责任公司 Compositions and methods for assessing risk of cancer development
EA037027B1 (en) * 2015-12-31 2021-01-27 Прогастрин Э Кансер С.А Р.Л. Use and method for preventing or treating gastric cancer using a composition comprising a monoclonal progastrin-binding antibody
EP3397964B1 (en) * 2015-12-31 2021-09-29 Progastrine et Cancers S.à r.l. Compositions and methods for detecting and treating ovarian cancer
SG11201908997UA (en) * 2017-03-30 2019-10-30 Ecs Progastrin Sa Compositions and methods for detecting prostate cancer
KR102616819B1 (en) * 2017-03-30 2023-12-21 프로가스트린 에 캔서스 에스.에이 알.엘. Compositions and methods for treating lung cancer
DK3720879T3 (en) * 2017-12-05 2022-06-20 Progastrine Et Cancers S A R L Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
JP7338128B2 (en) 2017-12-08 2023-09-05 イー、シー、エス、ビオトラッカー、エス、エー、アール、エル Radiolabeled progastrin in cancer diagnosis
TW201940881A (en) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 Combining progastrin detection with other cancer biomarkers in cancer diagnosis
EP3759492A1 (en) * 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
TWI793238B (en) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 Method and kit of detecting gastrogenic protein in biological sample in vitro
CN115785273B (en) * 2021-09-10 2023-10-31 东莞市朋志生物科技有限公司 Antibody for resisting pepsinogen I and application thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
MX9204374A (en) 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
WO2006032980A1 (en) * 2004-09-22 2006-03-30 Receptor Biologix, Inc. Monoclonal antibolies to progastrin
AU2007252986B2 (en) 2006-05-22 2013-03-21 Centre National De La Recherche Scientifique - Cnrs- Progastrin inhibitors in the treatment of colon cancer
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
LT2488551T (en) * 2009-10-16 2018-10-25 Progastrine Et Cancers S.A R.L. Monoclonal antibodies to progastrin and their uses

Also Published As

Publication number Publication date
US10385124B2 (en) 2019-08-20
HRP20181645T1 (en) 2018-12-14
CA2777691A1 (en) 2011-04-21
WO2011045080A2 (en) 2011-04-21
CU20120060A7 (en) 2013-04-19
NZ701709A (en) 2016-06-24
JP6272793B2 (en) 2018-01-31
SG10201704933PA (en) 2017-07-28
CN102791735B (en) 2016-05-18
NZ599971A (en) 2014-12-24
MA33747B1 (en) 2012-11-01
PL2488551T3 (en) 2019-01-31
RS57966B1 (en) 2019-01-31
EP2488551B1 (en) 2018-07-25
US9611320B2 (en) 2017-04-04
US20180022802A1 (en) 2018-01-25
JP2015145380A (en) 2015-08-13
IL219019A0 (en) 2012-06-28
TN2012000159A1 (en) 2013-12-12
EA029271B1 (en) 2018-03-30
CY1120913T1 (en) 2019-12-11
MX351635B (en) 2017-10-23
SI2488551T1 (en) 2019-01-31
KR20120091221A (en) 2012-08-17
DK2488551T3 (en) 2018-10-08
US10385125B2 (en) 2019-08-20
JP2013507138A (en) 2013-03-04
IL254004B2 (en) 2023-06-01
US20170174761A1 (en) 2017-06-22
US20170306012A1 (en) 2017-10-26
US10385126B2 (en) 2019-08-20
US20110117086A1 (en) 2011-05-19
EA201200597A1 (en) 2012-12-28
CU24196B1 (en) 2016-09-30
WO2011045080A3 (en) 2011-07-07
US11299542B2 (en) 2022-04-12
ES2690943T3 (en) 2018-11-23
US20170306011A1 (en) 2017-10-26
PL3421493T3 (en) 2024-04-29
US20220195035A1 (en) 2022-06-23
HK1178183A1 (en) 2013-09-06
AR078659A1 (en) 2011-11-23
GEP201706604B (en) 2017-01-25
ECSP12011796A (en) 2012-06-29
US20200002413A1 (en) 2020-01-02
KR20150082672A (en) 2015-07-15
ZA201202642B (en) 2013-06-26
JP5985987B2 (en) 2016-09-06
LT2488551T (en) 2018-10-25
BR112012008818B1 (en) 2021-10-19
PE20121649A1 (en) 2012-12-08
EP2488551A2 (en) 2012-08-22
IL219019B (en) 2019-05-30
CA2777691C (en) 2018-02-27
CR20120184A (en) 2012-08-20
EP3421493B1 (en) 2024-01-17
IL254004A0 (en) 2017-10-31
UA106771C2 (en) 2014-10-10
US10377821B2 (en) 2019-08-13
BR112012008818A2 (en) 2018-05-22
MX2012004400A (en) 2012-06-27
CN104628857A (en) 2015-05-20
AP2012006262A0 (en) 2012-06-30
EP3421493A1 (en) 2019-01-02
TWI537002B (en) 2016-06-11
EA201791876A1 (en) 2018-01-31
TW201119675A (en) 2011-06-16
JP2017212992A (en) 2017-12-07
AU2010306119A1 (en) 2012-05-03
EP3421493C0 (en) 2024-01-17
HN2012000708A (en) 2015-06-22
PT2488551T (en) 2018-10-31
CN102791735A (en) 2012-11-21
CL2012000914A1 (en) 2012-09-14
KR101640520B1 (en) 2016-07-19
GT201200114A (en) 2014-08-11
NI201200054A (en) 2012-08-20

Similar Documents

Publication Publication Date Title
IN2012DN03348A (en)
MX2020010639A (en) Humanized antibodies to liv-1 and use of same to treat cancer.
JO3097B1 (en) c-Met Antibodies
PH12014502419A1 (en) Specific binding proteins and uses thereof
MX2019004193A (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer.
NZ599737A (en) Il-17a antagonists
WO2009126934A3 (en) Detection and tratment of pancreatic, ovarian and other cancers
WO2010017515A3 (en) Breast cancer specific markers and methods of use
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
NZ626610A (en) Antibodies that bind csf1r
MX2012001782A (en) Combination therapy of an afucosylated cd20 antibody with bendamustine.
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
MX352373B (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof.
MX347463B (en) Combination therapy of an afucosylated cd20 antibody with an anti-vegf antibody.
MX339340B (en) Methods for predicting and improving the survival of gastric cancer patients.
WO2013149219A3 (en) Fully human antibodies that bind to vegfr2
TH133902A (en) Monoclonal Antibody for Progastrin and Uses of Monoclonal Antibody
TR201905240T4 (en) Humanized antibodies to LIV-1 and their use in the treatment of cancer.
UA104739C2 (en) c-MET ANTIBODIES